Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JQ1 + Silmitasertib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JQ1 | JQ-1 | BET Inhibitor (Pan) 33 | JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression, increased cell death, reduced macrophage immunosuppression, and inhibition of tumor growth (PMID: 24231268, PMID: 31018997, PMID: 30906568, PMID: 32800944). | |
| Silmitasertib | CX-4945|CX4945|CX 4945 | Silmitasertib (CX-4945) inhibits protein kinase CK2 (CSNK2), potentially resulting in decreased growth of tumor cells, alone and in combination with other agents (PMID: 21159648, PMID: 27758824, PMID: 32615532). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|